Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.
Type:
Grant
Filed:
July 25, 2011
Date of Patent:
August 16, 2016
Assignee:
GREEN CROSS CORPORATION
Inventors:
Se-Ho Kim, Kwang-Won Hong, Yong-Won Shin, Ki Hwan Chang, Min-Soo Kim, Jung-Ae Im
Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.
Type:
Grant
Filed:
January 9, 2015
Date of Patent:
June 21, 2016
Assignee:
GREEN CROSS CORPORATION
Inventors:
Soongyu Choi, Kwang-Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon Kim, Dong Ho Hong, Misuk Kang
Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
Type:
Application
Filed:
December 21, 2015
Publication date:
May 26, 2016
Applicants:
GREEN CROSS CORPORATION, MediGeneBio Corporation
Inventors:
Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
Abstract: The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.
Type:
Grant
Filed:
March 18, 2013
Date of Patent:
May 17, 2016
Assignee:
GREEN CROSS CORPORATION
Inventors:
Soongyu Choi, Jae Eun Kim, Kwang-Seop Song, Suk Ho Lee, Kisoo Park, Hee Jeong Seo, Min Ju Kim, Eun-Jung Park, So Ok Park, Younggyu Kong, Hyunku Kang, Ickhwan Son, Myung Eun Jung, Man-Young Cha, Hyun Jung Kim, Jun Sung Lee, Mi-Soon Kim, Min Woo Lee, Kinam Lee
Abstract: Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
Type:
Grant
Filed:
July 27, 2015
Date of Patent:
February 2, 2016
Assignees:
GREEN CROSS CORPORATION, MediGeneBio Corporation
Inventors:
Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
Abstract: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
Type:
Grant
Filed:
June 15, 2012
Date of Patent:
December 8, 2015
Assignees:
GREEN CROSS CORPORATION, MediGeneBio Corporation
Inventors:
Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.
Type:
Grant
Filed:
May 21, 2014
Date of Patent:
December 1, 2015
Assignee:
GREEN CROSS CORPORATION
Inventors:
Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
Abstract: Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
Type:
Application
Filed:
July 27, 2015
Publication date:
November 12, 2015
Applicants:
MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATION
Inventors:
Thong-Gyu JIN, Yo Kyung CHUNG, Sang Hoon PAIK, Yoo Chang PARK, Jinwook SEO, Yong Woon CHOI, Jong Mun SON, Yong-Chul KIM
Abstract: The present invention relates to epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-a, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.
Type:
Application
Filed:
March 27, 2013
Publication date:
August 20, 2015
Applicants:
MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE, GREEN CROSS CORPORATION
Inventors:
Se-Ho Kim, Kwang-Won Hong, Ki Hwan Chang, Min-soo Kim, Mi-Jung Lee, Jong-Hwa Won, Min-Kyu Hur, Hyun-Soo Cho, Ji-Ho Yoo
Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.
Type:
Application
Filed:
January 9, 2015
Publication date:
June 4, 2015
Applicant:
GREEN CROSS CORPORATION
Inventors:
Soongyu CHOI, Kwang-Seop SONG, Suk Ho LEE, Min Ju KIM, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, So Ok PARK, Hyunku KANG, Myung Eun JUNG, Kinam LEE, Hyun Jung KIM, Jun Sung LEE, Min Woo LEE, Mi-Soon KIM, Dong Ho HONG, Misuk KANG
Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.
Type:
Grant
Filed:
June 1, 2012
Date of Patent:
May 19, 2015
Assignee:
GREEN CROSS CORPORATION
Inventors:
Soongyu Choi, Kwang Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon Kim, Dong Ho Hong, Misuk Kang
Abstract: Provided are tumor-specific promoters, oncolytic virus vectors and a pharmaceutical composition comprising the virus vector. The virus vector comprising the novel tumor-specific promoter shows excellent oncolytic effects on tumor cells, and thus it is useful for treating a cancer.
Type:
Grant
Filed:
April 26, 2010
Date of Patent:
April 28, 2015
Assignees:
Green Cross Corporation, Mogam Biotechnology Research Institute, Industry-Academic Cooperation Foundation, Yonsei University
Abstract: The present invention relates to a novel compound with thiophene ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The prevention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating metabolic disorders, particularly diabetes.
Type:
Grant
Filed:
September 9, 2011
Date of Patent:
April 14, 2015
Assignee:
Green Cross Corporation
Inventors:
Jinhwa Lee, Kwang-Seop Song, Suk Ho Lee
Abstract: Disclosed is a novel C-aryl ansa compound having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. Also provided are a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.
Abstract: The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders.
Type:
Grant
Filed:
September 23, 2009
Date of Patent:
November 25, 2014
Assignee:
Green Cross Corporation
Inventors:
Jinhwa Lee, Suk Youn Kang, Eun-Jung Park, Kwang-Seop Song, Min Ju Kim, Hee Jeong Seo, Suk Ho Lee, Jeongmin Kim, Ae Nim Pae, Woo-Kyu Park
Abstract: A method for preparing a highly concentrated fibrinogen solution includes adding amino acid or amino acid derivatives, and/or salts to a lowly concentrated fibrinogen solution, followed by a ultra-filtration concentration. Factor XIII can be added either before or after the ultra-filtration to give a fibrin sealant component 1 containing the highly concentrated fibrinogen solution. The fibrin sealant component 1 could be preserved for a long time at room temperature and be used without a reconstitution. Fibrin sealant component 2 is a solution containing thrombin and calcium. A fibrin sealant product may be provided in a vial type in which the fibrin sealant components 1 and 2 are each filled in separate vials or in a re-filled syringe type wherein the fibrin sealant components 1 and 2 are each filled in separate syringes connected with each other to be instantly used.
Type:
Application
Filed:
October 24, 2012
Publication date:
November 6, 2014
Applicant:
GREEN CROSS CORPORATION
Inventors:
Jun Sic Kim, Gun Sul Lee, Ki-Yong Kim, Yong Kang, Ki Hwan Son
Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.
Type:
Grant
Filed:
July 8, 2010
Date of Patent:
September 23, 2014
Assignee:
Green Cross Corporation
Inventors:
Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
Abstract: The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.
Type:
Application
Filed:
March 18, 2013
Publication date:
September 18, 2014
Applicant:
GREEN CROSS CORPORATION
Inventors:
Soongyu CHOI, Jae Eun KIM, Kwang-Seop SONG, Suk Ho LEE, Kisoo PARK, Hee Jeong SEO, Min Ju KIM, Eun-Jung PARK, So Ok PARK, Younggyu KONG, Hyunku KANG, Ickhawn SON, Myung Eun JUNG, Man-Young CHA, Hyun Jung KIM, Jun Sung LEE, Mi-Soon KIM, Min Woo LEE, Kinam LEE
Abstract: A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.
Type:
Grant
Filed:
July 9, 2010
Date of Patent:
September 16, 2014
Assignee:
Green Cross Corporation
Inventors:
Jinhwa Lee, Hee Jeong Seo, Suk Youn Kang, Eun-Jung Park, Min Ju Kim, Suk Ho Lee, Jong Yup Kim, Jeongmin Kim, Myung Eun Jung, Hyun Jung Kim, Mi-soon Kim, Ho Kyun Han, Kwang Woo Ahn, Min Woo Lee, Ki-Nam Lee, Ae Nim Pae, Woo-Kyu Park
Abstract: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
Type:
Application
Filed:
June 15, 2012
Publication date:
August 28, 2014
Applicants:
MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATION
Inventors:
Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim